These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 23453210)

  • 1. L51. From immunosuppression to selective treatments: the benefit-risk ratio.
    Guillevin L
    Presse Med; 2013 Apr; 42(4 Pt 2):641-3. PubMed ID: 23453210
    [No Abstract]   [Full Text] [Related]  

  • 2. L44. Management of relapses in vasculitis.
    Mouthon L
    Presse Med; 2013 Apr; 42(4 Pt 2):619-22. PubMed ID: 23477710
    [No Abstract]   [Full Text] [Related]  

  • 3. L52. Vasculitis treatment: is it time to change the standard of care for ANCA-associated vasculitis?
    Hoffman GS
    Presse Med; 2013 Apr; 42(4 Pt 2):643-50. PubMed ID: 23474045
    [No Abstract]   [Full Text] [Related]  

  • 4. S3. Rituximab for ANCA-associated vasculitides: the French experience.
    Charles P; Guillevin L
    Presse Med; 2013 Apr; 42(4 Pt 2):534-6. PubMed ID: 23453207
    [No Abstract]   [Full Text] [Related]  

  • 5. S2. Rituximab for ANCA-associated vasculitis: the UK experience.
    Jayne D
    Presse Med; 2013 Apr; 42(4 Pt 2):532-4. PubMed ID: 23490639
    [No Abstract]   [Full Text] [Related]  

  • 6. Rituximab or cyclophosphamide in ANCA-associated renal vasculitis.
    Karassa FB
    N Engl J Med; 2010 Nov; 363(21):2073; author reply 2073-4. PubMed ID: 21083398
    [No Abstract]   [Full Text] [Related]  

  • 7. Treatment of ANCA-associated vasculitis: new therapies and a look at old entities.
    Zand L; Specks U; Sethi S; Fervenza FC
    Adv Chronic Kidney Dis; 2014 Mar; 21(2):182-93. PubMed ID: 24602467
    [TBL] [Abstract][Full Text] [Related]  

  • 8. S1. Rituximab for ANCA-associated vasculitis: the experience in the United States.
    Clain JM; Specks U
    Presse Med; 2013 Apr; 42(4 Pt 2):530-2. PubMed ID: 23477713
    [No Abstract]   [Full Text] [Related]  

  • 9. Therapy of polymyositis and dermatomyositis.
    Marie I
    Presse Med; 2011 Apr; 40(4 Pt 2):e257-70. PubMed ID: 21334847
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Rituximab for the treatment of ANCA associated vasculitis: the future today?].
    Alba MA; Flores-Suárez LF
    Reumatol Clin; 2011 Dec; 7 Suppl 3():S41-6. PubMed ID: 22115869
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Maintainance treatment of anti-neutrophil cytoplasm associated antibodies (ANCA)].
    Dábague Guzmán J; Pedroza Granados J; Zúñiga Varga J
    Reumatol Clin; 2011 Dec; 7 Suppl 3():S37-40. PubMed ID: 22119277
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The role of rituximab in the treatment of ANCA-associated systemic vasculitis].
    Roccatello D; Vangelista A; Pani A
    G Ital Nefrol; 2011; 28(5):474-88. PubMed ID: 22028261
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rituximab or cyclophosphamide in ANCA-associated renal vasculitis.
    Nossent JC
    N Engl J Med; 2010 Nov; 363(21):2072; author reply 2073-4. PubMed ID: 21083400
    [No Abstract]   [Full Text] [Related]  

  • 14. Rituximab or cyclophosphamide in ANCA-associated renal vasculitis.
    Hebert LA; Ardoin S; Shim RL
    N Engl J Med; 2010 Nov; 363(21):2072-3; author reply 2073-4. PubMed ID: 21083399
    [No Abstract]   [Full Text] [Related]  

  • 15. Rituximab or cyclophosphamide in ANCA-associated renal vasculitis.
    Schönermarck U; Rau S; Fischereder M
    N Engl J Med; 2010 Nov; 363(21):2072; author reply 2073-4. PubMed ID: 21083401
    [No Abstract]   [Full Text] [Related]  

  • 16. [Rituximab to treat ANCA-associated vasculitis].
    Guillevin L; Mahr A
    Rev Med Interne; 2011 Oct; 32(10):591-3. PubMed ID: 21872370
    [No Abstract]   [Full Text] [Related]  

  • 17. BSR and BHPR guideline for the management of adults with ANCA-associated vasculitis.
    Ntatsaki E; Carruthers D; Chakravarty K; D'Cruz D; Harper L; Jayne D; Luqmani R; Mills J; Mooney J; Venning M; Watts RA;
    Rheumatology (Oxford); 2014 Dec; 53(12):2306-9. PubMed ID: 24729399
    [No Abstract]   [Full Text] [Related]  

  • 18. Rituximab in combination with corticosteroids for the treatment of anti-neutrophil cytoplasmic antibody-associated vasculitis: a NICE single technology appraisal.
    Latimer NR; Carroll C; Wong R; Tappenden P; Venning MC; Luqmani R
    Pharmacoeconomics; 2014 Dec; 32(12):1171-83. PubMed ID: 25059204
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rituximab in ANCA-associated disease.
    Falk RJ; Jennette JC
    N Engl J Med; 2010 Jul; 363(3):285-6. PubMed ID: 20647204
    [No Abstract]   [Full Text] [Related]  

  • 20. Refractory disease in antineutrophil cytoplasmic antibodies associated vasculitis.
    Rutgers A; Kallenberg CG
    Curr Opin Rheumatol; 2012 May; 24(3):245-51. PubMed ID: 22410545
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.